| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Poland | 47 | 2021 | 2368 | 2.39 | Why? |
| Non-ST Elevated Myocardial Infarction | 7 | 2021 | 490 | 2.30 | Why? |
| Percutaneous Coronary Intervention | 18 | 2020 | 3646 | 1.71 | Why? |
| Myocardial Infarction | 14 | 2021 | 3361 | 1.68 | Why? |
| ST Elevation Myocardial Infarction | 11 | 2021 | 3051 | 1.63 | Why? |
| Defibrillators, Implantable | 5 | 2021 | 624 | 1.52 | Why? |
| Mountaineering | 2 | 2018 | 20 | 1.43 | Why? |
| Coronary Artery Disease | 15 | 2018 | 2570 | 1.37 | Why? |
| Registries | 29 | 2021 | 12327 | 1.33 | Why? |
| Coronary Artery Bypass | 8 | 2020 | 629 | 1.26 | Why? |
| Heart Ventricles | 4 | 2019 | 1139 | 1.17 | Why? |
| Heart Failure | 14 | 2021 | 6638 | 1.15 | Why? |
| Catheter Ablation | 3 | 2021 | 438 | 1.14 | Why? |
| Hypertension, Pulmonary | 3 | 2018 | 970 | 1.06 | Why? |
| Atrial Fibrillation | 7 | 2021 | 2320 | 1.04 | Why? |
| Lung Transplantation | 4 | 2019 | 1554 | 1.03 | Why? |
| Erythrocyte Indices | 3 | 2018 | 207 | 0.93 | Why? |
| Acute Coronary Syndrome | 7 | 2021 | 2107 | 0.90 | Why? |
| Shock, Cardiogenic | 3 | 2018 | 700 | 0.89 | Why? |
| Lung Diseases | 4 | 2019 | 2361 | 0.87 | Why? |
| Ablation Techniques | 2 | 2018 | 54 | 0.82 | Why? |
| Ventricular Dysfunction, Left | 2 | 2018 | 993 | 0.75 | Why? |
| Angioplasty, Balloon, Coronary | 6 | 2020 | 365 | 0.74 | Why? |
| Tachycardia, Atrioventricular Nodal Reentry | 1 | 2018 | 17 | 0.73 | Why? |
| Electric Countershock | 2 | 2020 | 284 | 0.72 | Why? |
| Atrioventricular Node | 1 | 2018 | 31 | 0.72 | Why? |
| Expeditions | 1 | 2017 | 14 | 0.72 | Why? |
| Intra-Aortic Balloon Pumping | 1 | 2018 | 125 | 0.70 | Why? |
| Mean Platelet Volume | 3 | 2018 | 203 | 0.69 | Why? |
| Cardiac Resynchronization Therapy Devices | 2 | 2017 | 64 | 0.68 | Why? |
| Reactive Nitrogen Species | 1 | 2016 | 36 | 0.68 | Why? |
| Hypothermia | 1 | 2017 | 59 | 0.67 | Why? |
| Tachycardia, Ventricular | 2 | 2018 | 251 | 0.66 | Why? |
| Cardiac Resynchronization Therapy | 2 | 2018 | 191 | 0.66 | Why? |
| Altitude | 2 | 2018 | 311 | 0.65 | Why? |
| Coronary Angiography | 12 | 2021 | 2275 | 0.64 | Why? |
| Heart Neoplasms | 1 | 2017 | 77 | 0.64 | Why? |
| Electrocardiography | 6 | 2021 | 3957 | 0.63 | Why? |
| Coronary Thrombosis | 1 | 2021 | 433 | 0.62 | Why? |
| Tricuspid Valve | 1 | 2017 | 91 | 0.62 | Why? |
| Diabetes Mellitus, Type 2 | 5 | 2019 | 6166 | 0.60 | Why? |
| Echocardiography | 3 | 2019 | 3661 | 0.59 | Why? |
| Resistance Training | 1 | 2018 | 273 | 0.58 | Why? |
| Pneumonectomy | 1 | 2018 | 278 | 0.55 | Why? |
| Secondary Prevention | 3 | 2018 | 762 | 0.55 | Why? |
| Sarcoma | 1 | 2017 | 290 | 0.54 | Why? |
| Bradycardia | 1 | 2017 | 292 | 0.53 | Why? |
| Genetic Testing | 1 | 2017 | 395 | 0.53 | Why? |
| Natriuretic Peptide, Brain | 2 | 2018 | 1215 | 0.53 | Why? |
| Stroke Volume | 4 | 2018 | 2153 | 0.51 | Why? |
| Erythrocytes | 2 | 2018 | 617 | 0.50 | Why? |
| Monitoring, Ambulatory | 1 | 2017 | 343 | 0.49 | Why? |
| Blood Platelets | 4 | 2018 | 1704 | 0.49 | Why? |
| Ventricular Function, Left | 3 | 2018 | 1555 | 0.49 | Why? |
| Multimorbidity | 1 | 2017 | 703 | 0.48 | Why? |
| Emergency Medical Services | 5 | 2020 | 3557 | 0.47 | Why? |
| Iron | 1 | 2018 | 619 | 0.47 | Why? |
| Death, Sudden, Cardiac | 1 | 2017 | 522 | 0.47 | Why? |
| Ischemia | 2 | 2017 | 901 | 0.46 | Why? |
| Public Health Practice | 1 | 2020 | 945 | 0.45 | Why? |
| Male | 69 | 2021 | 367725 | 0.44 | Why? |
| Contrast Media | 1 | 2017 | 1011 | 0.44 | Why? |
| Brain Ischemia | 4 | 2019 | 2813 | 0.42 | Why? |
| Peptide Fragments | 2 | 2018 | 2075 | 0.41 | Why? |
| Middle Aged | 60 | 2021 | 270681 | 0.41 | Why? |
| Patient Transfer | 1 | 2017 | 898 | 0.40 | Why? |
| Atrial Flutter | 2 | 2021 | 143 | 0.39 | Why? |
| Exercise Therapy | 1 | 2018 | 976 | 0.39 | Why? |
| Prognosis | 19 | 2019 | 32490 | 0.38 | Why? |
| Intracranial Hemorrhages | 1 | 2018 | 1170 | 0.38 | Why? |
| Female | 64 | 2020 | 380317 | 0.38 | Why? |
| Cardiac Catheterization | 4 | 2020 | 882 | 0.36 | Why? |
| Out-of-Hospital Cardiac Arrest | 1 | 2018 | 1047 | 0.36 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.36 | Why? |
| Waiting Lists | 1 | 2017 | 1388 | 0.36 | Why? |
| Aged | 45 | 2021 | 215776 | 0.35 | Why? |
| Humans | 96 | 2021 | 930598 | 0.35 | Why? |
| Inflammation Mediators | 1 | 2019 | 2654 | 0.33 | Why? |
| Systole | 2 | 2018 | 252 | 0.32 | Why? |
| Lymphocyte Count | 2 | 2017 | 4758 | 0.32 | Why? |
| Blood Pressure | 1 | 2018 | 2198 | 0.32 | Why? |
| Hypoxia | 2 | 2018 | 3626 | 0.31 | Why? |
| Feeding Behavior | 1 | 2018 | 1909 | 0.30 | Why? |
| Diet | 1 | 2018 | 2052 | 0.30 | Why? |
| Patient Discharge | 2 | 2021 | 5696 | 0.30 | Why? |
| Treatment Outcome | 25 | 2020 | 51732 | 0.30 | Why? |
| Inflammation | 3 | 2019 | 13255 | 0.30 | Why? |
| Remote Consultation | 1 | 2020 | 2396 | 0.29 | Why? |
| ROC Curve | 4 | 2018 | 6024 | 0.29 | Why? |
| Cardiopulmonary Resuscitation | 1 | 2018 | 1876 | 0.29 | Why? |
| Risk Factors | 22 | 2019 | 71621 | 0.28 | Why? |
| Lymphocytes | 1 | 2017 | 3056 | 0.28 | Why? |
| Stroke | 5 | 2019 | 8839 | 0.27 | Why? |
| Family | 1 | 2018 | 2909 | 0.27 | Why? |
| Cholesterol, LDL | 2 | 2018 | 499 | 0.27 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2018 | 1969 | 0.26 | Why? |
| Arrhythmias, Cardiac | 1 | 2017 | 2510 | 0.26 | Why? |
| Coronary Stenosis | 2 | 2019 | 273 | 0.24 | Why? |
| Biomarkers | 7 | 2019 | 23361 | 0.24 | Why? |
| Drug-Eluting Stents | 2 | 2019 | 562 | 0.24 | Why? |
| Cardiovascular Agents | 2 | 2018 | 663 | 0.24 | Why? |
| Propensity Score | 4 | 2018 | 2690 | 0.24 | Why? |
| Time Factors | 16 | 2020 | 31397 | 0.24 | Why? |
| Retrospective Studies | 23 | 2021 | 105322 | 0.23 | Why? |
| Dyslipidemias | 2 | 2018 | 791 | 0.22 | Why? |
| Kaplan-Meier Estimate | 5 | 2018 | 4260 | 0.22 | Why? |
| Hospitalization | 8 | 2020 | 54280 | 0.22 | Why? |
| Diabetes Mellitus | 3 | 2018 | 8207 | 0.22 | Why? |
| Adult | 21 | 2020 | 244371 | 0.22 | Why? |
| Molecular Diagnostic Techniques | 1 | 2017 | 4239 | 0.22 | Why? |
| Idiopathic Pulmonary Fibrosis | 2 | 2019 | 595 | 0.21 | Why? |
| Patient Admission | 2 | 2017 | 5250 | 0.21 | Why? |
| Ambulances | 2 | 2020 | 287 | 0.21 | Why? |
| Multiple Sclerosis | 1 | 2016 | 2600 | 0.21 | Why? |
| Pulmonary Disease, Chronic Obstructive | 4 | 2019 | 3832 | 0.21 | Why? |
| Sirolimus | 2 | 2019 | 240 | 0.20 | Why? |
| Follow-Up Studies | 7 | 2018 | 17020 | 0.19 | Why? |
| Popliteal Artery | 1 | 2018 | 32 | 0.19 | Why? |
| Serum Globulins | 1 | 2018 | 20 | 0.19 | Why? |
| Self Expandable Metallic Stents | 1 | 2019 | 52 | 0.19 | Why? |
| Proportional Hazards Models | 5 | 2018 | 6543 | 0.19 | Why? |
| Patient Readmission | 2 | 2018 | 1543 | 0.19 | Why? |
| Obesity | 2 | 2019 | 7388 | 0.18 | Why? |
| Emergency Medical Dispatcher | 1 | 2018 | 11 | 0.18 | Why? |
| Angioplasty, Balloon | 1 | 2018 | 66 | 0.18 | Why? |
| Paclitaxel | 1 | 2018 | 124 | 0.18 | Why? |
| Lipomatosis, Multiple Symmetrical | 1 | 2017 | 4 | 0.18 | Why? |
| Diet Surveys | 1 | 2018 | 152 | 0.18 | Why? |
| Iohexol | 1 | 2017 | 42 | 0.18 | Why? |
| Atherectomy, Coronary | 1 | 2018 | 35 | 0.18 | Why? |
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2017 | 33 | 0.18 | Why? |
| Trimetazidine | 1 | 2017 | 5 | 0.17 | Why? |
| Coated Materials, Biocompatible | 1 | 2018 | 113 | 0.17 | Why? |
| Edetic Acid | 1 | 2017 | 85 | 0.17 | Why? |
| Erythrocyte Count | 1 | 2018 | 137 | 0.17 | Why? |
| Matrix Metalloproteinase 2 | 1 | 2017 | 85 | 0.17 | Why? |
| Cardiovascular Diseases | 3 | 2020 | 11497 | 0.17 | Why? |
| Vascular Access Devices | 1 | 2018 | 122 | 0.17 | Why? |
| Acute Kidney Injury | 1 | 2017 | 5762 | 0.17 | Why? |
| Citric Acid | 1 | 2017 | 116 | 0.17 | Why? |
| C-Reactive Protein | 3 | 2019 | 7972 | 0.16 | Why? |
| Chi-Square Distribution | 2 | 2017 | 961 | 0.16 | Why? |
| Hyperglycemia | 1 | 2008 | 1363 | 0.16 | Why? |
| Lung Diseases, Interstitial | 2 | 2019 | 1476 | 0.16 | Why? |
| Femoral Artery | 1 | 2018 | 213 | 0.16 | Why? |
| Cytokines | 1 | 2019 | 15010 | 0.16 | Why? |
| Cerebral Infarction | 1 | 2019 | 245 | 0.16 | Why? |
| Organ Size | 1 | 2017 | 384 | 0.16 | Why? |
| Matrix Metalloproteinase 9 | 1 | 2017 | 211 | 0.16 | Why? |
| Hypercholesterolemia | 1 | 2018 | 175 | 0.16 | Why? |
| Odds Ratio | 2 | 2018 | 5861 | 0.15 | Why? |
| Epidemiology | 1 | 2018 | 216 | 0.15 | Why? |
| Multivariate Analysis | 4 | 2018 | 5440 | 0.15 | Why? |
| Absorbable Implants | 1 | 2018 | 191 | 0.15 | Why? |
| Pulmonary Veins | 1 | 2017 | 146 | 0.15 | Why? |
| Serum Amyloid P-Component | 1 | 2017 | 193 | 0.15 | Why? |
| Diabetic Angiopathies | 1 | 2017 | 146 | 0.15 | Why? |
| Natalizumab | 1 | 2016 | 144 | 0.15 | Why? |
| Carotid Artery Diseases | 1 | 2019 | 251 | 0.15 | Why? |
| Esophagus | 1 | 2017 | 139 | 0.15 | Why? |
| Hypolipidemic Agents | 1 | 2017 | 208 | 0.15 | Why? |
| Sex Factors | 5 | 2019 | 11014 | 0.15 | Why? |
| Coronary Occlusion | 1 | 2017 | 138 | 0.15 | Why? |
| Cardiologists | 1 | 2020 | 366 | 0.15 | Why? |
| Fingolimod Hydrochloride | 1 | 2016 | 217 | 0.14 | Why? |
| Aged, 80 and over | 12 | 2021 | 88759 | 0.14 | Why? |
| Myocardial Revascularization | 1 | 2017 | 267 | 0.14 | Why? |
| Interleukin-2 | 1 | 2017 | 443 | 0.14 | Why? |
| Sodium | 1 | 2017 | 309 | 0.14 | Why? |
| Survival Rate | 3 | 2019 | 9206 | 0.14 | Why? |
| Kidney Function Tests | 1 | 2017 | 520 | 0.14 | Why? |
| Predictive Value of Tests | 5 | 2019 | 9537 | 0.14 | Why? |
| Telemetry | 1 | 2017 | 240 | 0.14 | Why? |
| Serum Albumin | 1 | 2018 | 571 | 0.14 | Why? |
| Adaptation, Physiological | 1 | 2017 | 359 | 0.14 | Why? |
| Interferon beta-1b | 1 | 2016 | 274 | 0.14 | Why? |
| Blood Pressure Determination | 1 | 2018 | 450 | 0.13 | Why? |
| Walk Test | 1 | 2017 | 461 | 0.13 | Why? |
| Polymers | 1 | 2018 | 507 | 0.13 | Why? |
| Uric Acid | 1 | 2017 | 285 | 0.13 | Why? |
| Interferon beta-1a | 1 | 2016 | 316 | 0.13 | Why? |
| Cardiology Service, Hospital | 1 | 2020 | 602 | 0.13 | Why? |
| Inhalation Exposure | 1 | 2018 | 405 | 0.13 | Why? |
| Stroke Rehabilitation | 1 | 2017 | 299 | 0.13 | Why? |
| Cause of Death | 2 | 2017 | 4823 | 0.12 | Why? |
| Peripheral Arterial Disease | 1 | 2018 | 471 | 0.12 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.12 | Why? |
| Pilot Projects | 3 | 2018 | 5182 | 0.12 | Why? |
| Recurrence | 2 | 2019 | 3675 | 0.11 | Why? |
| Pulmonary Edema | 1 | 2016 | 430 | 0.11 | Why? |
| Lipids | 1 | 2018 | 1079 | 0.11 | Why? |
| Aftercare | 1 | 2021 | 1637 | 0.11 | Why? |
| Glomerular Filtration Rate | 1 | 2017 | 1262 | 0.11 | Why? |
| Fatal Outcome | 1 | 2021 | 3438 | 0.11 | Why? |
| Telemedicine | 2 | 2020 | 25032 | 0.11 | Why? |
| Creatinine | 1 | 2017 | 1443 | 0.11 | Why? |
| Interleukin-8 | 1 | 2017 | 964 | 0.11 | Why? |
| Primary Prevention | 1 | 2018 | 778 | 0.11 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.11 | Why? |
| Heart Transplantation | 2 | 2018 | 1293 | 0.11 | Why? |
| Practice Patterns, Physicians' | 2 | 2020 | 4927 | 0.10 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.10 | Why? |
| Healthcare Disparities | 2 | 2019 | 3893 | 0.10 | Why? |
| Glycated Hemoglobin A | 1 | 2018 | 1316 | 0.10 | Why? |
| Aortic Valve Stenosis | 1 | 2018 | 741 | 0.10 | Why? |
| Prospective Studies | 8 | 2018 | 43301 | 0.10 | Why? |
| Air Pollutants | 2 | 2018 | 3110 | 0.10 | Why? |
| Sensitivity and Specificity | 4 | 2018 | 22971 | 0.10 | Why? |
| Area Under Curve | 1 | 2017 | 2564 | 0.10 | Why? |
| Alcoholism | 1 | 2017 | 691 | 0.10 | Why? |
| Incidence | 4 | 2017 | 25622 | 0.10 | Why? |
| Survival Analysis | 3 | 2019 | 7592 | 0.10 | Why? |
| Blood Glucose | 2 | 2018 | 3642 | 0.10 | Why? |
| Nitric Oxide | 1 | 2016 | 769 | 0.10 | Why? |
| Respiratory Function Tests | 1 | 2017 | 1755 | 0.10 | Why? |
| Pakistan | 1 | 2017 | 2302 | 0.10 | Why? |
| Aspirin | 1 | 2017 | 1043 | 0.09 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.09 | Why? |
| Heart-Assist Devices | 1 | 2017 | 812 | 0.09 | Why? |
| Recovery of Function | 1 | 2018 | 2461 | 0.09 | Why? |
| Heart Conduction System | 1 | 2010 | 266 | 0.09 | Why? |
| Platelet Count | 3 | 2018 | 1381 | 0.08 | Why? |
| Young Adult | 4 | 2019 | 93724 | 0.08 | Why? |
| Environmental Exposure | 1 | 2018 | 1558 | 0.08 | Why? |
| Databases, Factual | 2 | 2020 | 6248 | 0.08 | Why? |
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2018 | 1510 | 0.08 | Why? |
| Comorbidity | 4 | 2021 | 34796 | 0.08 | Why? |
| Autopsy | 1 | 2017 | 3495 | 0.07 | Why? |
| Body Mass Index | 1 | 2019 | 4306 | 0.07 | Why? |
| Particulate Matter | 1 | 2018 | 3249 | 0.07 | Why? |
| Length of Stay | 2 | 2020 | 11042 | 0.07 | Why? |
| Prosthesis Design | 2 | 2018 | 594 | 0.07 | Why? |
| Guideline Adherence | 1 | 2018 | 2309 | 0.07 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.07 | Why? |
| Risk | 1 | 2016 | 5288 | 0.07 | Why? |
| Models, Biological | 2 | 2018 | 4907 | 0.07 | Why? |
| Age Factors | 5 | 2019 | 21039 | 0.07 | Why? |
| Disease Management | 2 | 2020 | 6841 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2018 | 7220 | 0.06 | Why? |
| Heart Diseases | 1 | 2020 | 3503 | 0.06 | Why? |
| Severity of Illness Index | 4 | 2018 | 48226 | 0.06 | Why? |
| Adolescent | 3 | 2018 | 86841 | 0.06 | Why? |
| Risk Assessment | 5 | 2019 | 25439 | 0.06 | Why? |
| Vitamin D | 1 | 2018 | 2904 | 0.06 | Why? |
| Cardiology | 1 | 2018 | 2873 | 0.06 | Why? |
| Renal Insufficiency, Chronic | 1 | 2017 | 2654 | 0.06 | Why? |
| Pandemics | 12 | 2021 | 389249 | 0.06 | Why? |
| Antineoplastic Agents | 1 | 2017 | 3550 | 0.06 | Why? |
| Societies, Medical | 1 | 2018 | 6907 | 0.05 | Why? |
| Exercise | 2 | 2018 | 6771 | 0.05 | Why? |
| Managed Care Programs | 1 | 2021 | 62 | 0.05 | Why? |
| Tissue Plasminogen Activator | 2 | 2017 | 778 | 0.05 | Why? |
| Socioeconomic Factors | 1 | 2018 | 8495 | 0.05 | Why? |
| Defibrillators | 1 | 2021 | 144 | 0.05 | Why? |
| Time-to-Treatment | 1 | 2017 | 5883 | 0.05 | Why? |
| Physicians | 1 | 2019 | 4214 | 0.05 | Why? |
| Cobalt | 1 | 2019 | 33 | 0.05 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2019 | 10649 | 0.05 | Why? |
| Chromium | 1 | 2019 | 27 | 0.05 | Why? |
| Ambulatory Care | 1 | 2017 | 4947 | 0.05 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.05 | Why? |
| Health Status Disparities | 1 | 2017 | 4072 | 0.05 | Why? |
| Fibrinolytic Agents | 3 | 2017 | 1702 | 0.05 | Why? |
| Vascular Patency | 1 | 2018 | 96 | 0.05 | Why? |
| Thrombolytic Therapy | 3 | 2017 | 2218 | 0.05 | Why? |
| Myocardial Reperfusion | 2 | 2010 | 168 | 0.05 | Why? |
| Hospitals | 1 | 2018 | 11793 | 0.05 | Why? |
| Citrates | 1 | 2017 | 37 | 0.04 | Why? |
| Nitrogen Oxides | 1 | 2018 | 72 | 0.04 | Why? |
| Combined Modality Therapy | 2 | 2018 | 3395 | 0.04 | Why? |
| Sulfur Dioxide | 1 | 2018 | 99 | 0.04 | Why? |
| Constriction, Pathologic | 1 | 2018 | 212 | 0.04 | Why? |
| Hospital Mortality | 6 | 2019 | 22087 | 0.04 | Why? |
| Platelet-Rich Plasma | 1 | 2017 | 91 | 0.04 | Why? |
| Everolimus | 1 | 2018 | 215 | 0.04 | Why? |
| Carbon Monoxide | 1 | 2018 | 167 | 0.04 | Why? |
| Hypertension | 1 | 2018 | 8895 | 0.04 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.04 | Why? |
| Platelet Function Tests | 1 | 2017 | 231 | 0.04 | Why? |
| Quality of Life | 1 | 2017 | 9820 | 0.04 | Why? |
| Diabetes Complications | 1 | 2008 | 2358 | 0.04 | Why? |
| Emergency Service, Hospital | 1 | 2020 | 14232 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Platelet Aggregation | 1 | 2017 | 318 | 0.04 | Why? |
| Allied Health Personnel | 1 | 2019 | 416 | 0.04 | Why? |
| Postoperative Period | 1 | 2017 | 651 | 0.04 | Why? |
| Single-Blind Method | 1 | 2018 | 1283 | 0.03 | Why? |
| Cross-Sectional Studies | 2 | 2018 | 53120 | 0.03 | Why? |
| China | 2 | 2020 | 50654 | 0.03 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.03 | Why? |
| Global Health | 1 | 2017 | 13911 | 0.03 | Why? |
| Women's Health | 1 | 2018 | 444 | 0.03 | Why? |
| Stress, Physiological | 1 | 2017 | 378 | 0.03 | Why? |
| Multicenter Studies as Topic | 1 | 2019 | 2437 | 0.03 | Why? |
| Infection Control | 1 | 2021 | 23131 | 0.03 | Why? |
| Patient Selection | 2 | 2018 | 4560 | 0.03 | Why? |
| Lung | 1 | 2019 | 31049 | 0.02 | Why? |
| Ozone | 1 | 2018 | 757 | 0.02 | Why? |
| Coronary Vessels | 1 | 2017 | 914 | 0.02 | Why? |
| Survivors | 1 | 2021 | 2619 | 0.02 | Why? |
| Professional Role | 1 | 2018 | 1280 | 0.02 | Why? |
| Medical Records | 1 | 2010 | 513 | 0.02 | Why? |
| Cost-Benefit Analysis | 1 | 2018 | 2259 | 0.02 | Why? |
| Needs Assessment | 1 | 2018 | 2352 | 0.02 | Why? |
| Statistics, Nonparametric | 1 | 2010 | 1008 | 0.02 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2017 | 1671 | 0.02 | Why? |
| Forecasting | 1 | 2020 | 4492 | 0.02 | Why? |
| Thrombectomy | 1 | 2017 | 2272 | 0.02 | Why? |
| Japan | 1 | 2018 | 6653 | 0.02 | Why? |
| Life Style | 1 | 2017 | 2708 | 0.02 | Why? |
| Health Promotion | 1 | 2018 | 2020 | 0.02 | Why? |
| Health Status | 1 | 2017 | 3259 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Research Design | 1 | 2019 | 5830 | 0.01 | Why? |
| Mortality | 1 | 2018 | 7132 | 0.01 | Why? |
| Air Pollution | 1 | 2018 | 3504 | 0.01 | Why? |
| Disease Progression | 1 | 2018 | 13580 | 0.01 | Why? |
| Age Distribution | 1 | 2008 | 3567 | 0.01 | Why? |
| Prevalence | 1 | 2018 | 25773 | 0.01 | Why? |
| Cohort Studies | 1 | 2017 | 36005 | 0.01 | Why? |
| Surveys and Questionnaires | 1 | 2017 | 43792 | 0.01 | Why? |
| Child | 1 | 2018 | 70012 | 0.01 | Why? |